The neoadjuvant approach in resectable pancreatic ductal adenocarcinoma: lessons learned
The PRODIGE24/CCTG-PA.6 adjuvant trial demonstrated the longest median overall survival reported to date of 53·5 months (95% CI 43·5–58·4) in a select cohort and documented the importance of completing adjuvant therapy.
In addition, up to 25% of patients might have metastatic disease on early postoperative imaging.
A test of biology allows for selection of those most likely to benefit from surgery. However, we still do not have evidence from randomised controlled trials to support the use of neoadjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma (table). In this regard, Knut Jørgen Labori and colleagues are to be congratulated on conducting the exploratory multicentre, randomised, phase 2 NORPACT-1 trial evaluating the role of neoadjuvant fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) followed by surgery versus surgery and adjuvant chemotherapy (physicians’ choice), the results of which are reported in The Lancet Gastroenterology & Hepatology.
| Patient population | Groups | Number of cycles of neoadjuvant chemotherapy | Number of patients | Patients completing neoadjuvant chemotherapy by ITT | Median overall survival, months | |
|---|---|---|---|---|---|---|
| SWOG1505 | Resectable | Neoadjuvant modified FOLFIRINOX vs neoadjuvant gemcitabine and abraxane | 6 vs 3 | 55 vs 47 | 46 (84%) vs 40 (85%) | 23·6 vs 23·2 |
| Prep-02/JSAP-05 | Resectable and borderline resectable | Neoadjuvant gemcitabine plus S-1 vs upfront surgery | 2 vs NA | 182 vs 180 | Not reported | 36·7 vs 26·6 |
| NEONAX | Resectable | Neoadjuvant gemcitabine and abraxane vs upfront surgery | 2 vs NA | 59 vs 59 | 53 (90%) | 25·5 vs 16·7 |
| PREOPANC-1 | Resectable and borderline resectable | Neoadjuvant gemcitabine and radiotherapy vs upfront surgery | 3 vs NA | 119 vs 127 | 81 (68%) | 15·7% (20·5)
vs 14·3% (6·5) |
| PANACHE01
PRODIGE48 |
Resectable | Neoadjuvant modified FOLFIRINOX vs neoadjuvant FOLFOX vs upfront surgery | 4 vs 4 vs NA | 70 vs 50 vs 26 | 62 (88%) vs 42 (84%) | 30·6 vs 31·3 vs >36 |
| PREOPANC-2 | Resectable and borderline resectable | Neoadjuvant full-dose FOLFIRINOX vs neoadjuvant gemcitabine and radiotherapy | 8 vs 3 | 185 vs 184 | 115 (62%) vs 149 (81%) | 21·9 vs 21·3 |
| NORPACT-1 | Resectable | Neoadjuvant full-dose FOLFIRINOX vs upfront surgery | 4 vs NA | 77 vs 63 | 36 (46%) | 25·1 vs 38·5 |

